Calcium
Calcium channels have long been the target of therapeutic drugs aimed at treating the symptoms of cardiovascular disease and migraine headache. They regulate the permeability of the cell membrane towards calcium. Axon Medchem offers pharmacological standards that interact at each of the 2 main classes within the family of calcium channels, the voltage-gated, and the ligand-gated channels.[1].
[1] InternationalUnion of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels. WA Catterall, E Perez-Reyes, TP Snutch, J Striessnig. Pharmacol Rev 57:411–425, 2005
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1697 | BAY K 8644 | Calcium (Ca2+) channel activator (L-type voltage-gated) | €95.00 | |
| 1758 | BAY K 8644, (R)-(+)- | Calcium (Ca2+) channel modulator | €115.00 | |
| 1759 | BAY K 8644, (S)-(-)- | Calcium (Ca2+) channel activator (L-type voltage-gated) | €115.00 | |
| 1868 | CRAC inhibitor 44 | Potent and selective CRAC ion channel blocker | €110.00 | |
| 1448 | Felodipine | Ca2+ channel blocker | €65.00 | |
| 2068 | Nifedipine | Ca2+ channel blocker (L-type voltage gated) | €55.00 | |
| 1823 | Pregabalin | Reduces synaptic signaling by binding to α2δ subunits | €95.00 | |
| 1221 | SKF 96365 hydrochloride | Ca2+ channel blocker | €105.00 | |